RESUMO
MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells. NCOR2 is a transcriptional coregulatory protein and its role in MM remains unknown. To define the role of NCOR2 in MM, we created NCOR2 knockout human myeloma cell lines and demonstrated that NCOR2 knockout led to high MYC expression. Furthermore, NCOR2 knockout conferred resistance to pomalidomide, BET and HDAC inhibitors, independent of Cereblon (CRBN), indicating high MYC expression as a cause of multidrug resistance. Moreover, NCOR2 interacted with the nucleosome remodeling and deacetylase (NuRD) complex and repressed the expression of CD180 by directly binding to its promoter and inducing MYC expression. Next, we generated lenalidomide-resistant and pomalidomide-resistant human myeloma cell lines. Whole-exome sequencing revealed that these cell lines acquired the same exonic mutations of NCOR2. These cell lines showed NCOR2 downregulation and MYC upregulation independent of CRBN and demonstrated resistance to BET and HDAC inhibitors. Our findings reveal a novel CRBN independent molecular mechanism associated with drug resistance. Low NCOR2 expression can serve as a potential biomarker for drug resistance and needs further validation in larger prospective studies.
Assuntos
Resistencia a Medicamentos Antineoplásicos , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/genética , Correpressor 2 de Receptor Nuclear/genética , Proteínas Proto-Oncogênicas c-myc/genética , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Resistência a Múltiplos Medicamentos , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Técnicas de Inativação de Genes , Inibidores de Histona Desacetilases/farmacologia , Humanos , Talidomida/análogos & derivados , Talidomida/farmacologia , Regulação para Cima/efeitos dos fármacosRESUMO
Recent genetic studies identified that the disease-specific G17V RHOA mutation, together with mutations in TET2, DNMT3A, and IDH2, is a hallmark of angioimmunoblastic T cell lymphomas (AITL). The diagnostic value of these mutations is now being investigated. Circulating tumor DNAs (ctDNAs) may offer a non-invasive testing for diagnosis and disease monitoring of cancers. To investigate whether these mutations are useful markers for ctDNAs in AITL and its related lymphomas, we performed targeted sequencing for TET2, RHOA, DNMT3A, and IDH2 in paired tumors and cell-free DNAs from 14 patients at diagnosis. Eighty-three percent of mutations detected in tumors were also observed in cell-free DNAs. During the disease course, mutations were detectable in cell-free DNAs in a refractory case, while they disappeared in a chemosensitive case. These data suggest that the disease-specific gene mutations serve as sensitive indicators for ctDNAs and may also be applicable for non-invasive monitoring of minimal residual diseases in AITL.
Assuntos
DNA de Neoplasias/sangue , Linfoma de Células T/sangue , DNA (Citosina-5-)-Metiltransferases/genética , DNA Metiltransferase 3A , DNA de Neoplasias/genética , Proteínas de Ligação a DNA/genética , Dioxigenases , Feminino , Humanos , Isocitrato Desidrogenase/genética , Linfoma de Células T/diagnóstico , Linfoma de Células T/genética , Masculino , Proteínas Proto-Oncogênicas/genética , Proteína rhoA de Ligação ao GTP/genéticaAssuntos
Neoplasias do Sistema Nervoso Central/genética , Neoplasias do Sistema Nervoso Central/mortalidade , Linfoma/genética , Linfoma/mortalidade , Mutação , Fator 88 de Diferenciação Mieloide/genética , Biomarcadores Tumorais , Neoplasias do Sistema Nervoso Central/terapia , Humanos , Linfoma/terapia , Prognóstico , Modelos de Riscos Proporcionais , Fatores de RiscoRESUMO
Hydroxymethylcytosine (hmC) is a natural nucleobase, which is converted from methylcytosine (mC) by tet methylcytosine dioxygenase (TET) family (TET1-3) enzymes. Decrease of genomic hmC is postulated to confer a risk for myeloid-lineage as well as T-cell neoplasms, based on the fact that loss-of-function mutations in the TET2 gene were frequently identified in these diseases. The relationship between hmC and aging remains to be elucidated. Here, we demonstrated that hmC content decreased with age in the peripheral blood T cells of 53 human volunteers. We further identified that the mRNA expression levels of TET1 and TET3 decreased with age, while those of TET2 were not influenced by age. The genomic hmC content was correlated with the mRNA expression level of TET3, but not those of TET1 and TET2. Our study suggests the presence of new epigenetic regulatory mechanisms in aging T cells.
Assuntos
Metilação de DNA , Epigênese Genética , Linfócitos T/metabolismo , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Proteínas de Ligação a DNA/genética , Dioxigenases/genética , Expressão Gênica , Voluntários Saudáveis , Humanos , Pessoa de Meia-Idade , Oxigenases de Função Mista , Proteínas Proto-Oncogênicas/genética , RNA Mensageiro/genética , Subpopulações de Linfócitos T/metabolismo , Adulto JovemAssuntos
DNA (Citosina-5-)-Metiltransferases/genética , Proteínas de Ligação a DNA/genética , Linfoma de Células T Periférico/diagnóstico , Linfoma de Células T Periférico/genética , Mutação/genética , Proteínas Proto-Oncogênicas/genética , Idoso , DNA Metiltransferase 3A , Dioxigenases , Humanos , MasculinoRESUMO
Angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) are subtypes of T-cell lymphoma. Due to low tumor cell content and substantial reactive cell infiltration, these lymphomas are sometimes mistaken for other types of lymphomas or even non-neoplastic diseases. In addition, a significant proportion of PTCL-NOS cases reportedly exhibit features of AITL (AITL-like PTCL-NOS). Thus disagreement is common in distinguishing between AITL and PTCL-NOS. Using whole-exome and subsequent targeted sequencing, we recently identified G17V RHOA mutations in 60-70% of AITL and AITL-like PTCL-NOS cases but not in other hematologic cancers, including other T-cell malignancies. Here, we establish a sensitive detection method for the G17V RHOA mutation using a quantitative allele-specific polymerase chain reaction (qAS-PCR) assay. Mutated allele frequencies deduced from this approach were highly correlated with those determined by deep sequencing. This method could serve as a novel diagnostic tool for 60-70% of AITL and AITL-like PTCL-NOS.
Assuntos
Análise Mutacional de DNA/métodos , Linfoma de Células T/diagnóstico , Mutação de Sentido Incorreto , Reação em Cadeia da Polimerase/métodos , Proteína rhoA de Ligação ao GTP/genética , Alelos , Exoma , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Linfoma de Células T/classificação , Linfoma de Células T/genéticaRESUMO
Angioimmunoblastic T cell lymphoma (AITL) is a distinct subtype of peripheral T cell lymphoma characterized by generalized lymphadenopathy and frequent autoimmune-like manifestations. Although frequent mutations in TET2, IDH2 and DNMT3A, which are common to various hematologic malignancies, have been identified in AITL, the molecular pathogenesis specific to this lymphoma subtype is unknown. Here we report somatic RHOA mutations encoding a p.Gly17Val alteration in 68% of AITL samples. Remarkably, all cases with the mutation encoding p.Gly17Val also had TET2 mutations. The RHOA mutation encoding p.Gly17Val was specifically identified in tumor cells, whereas TET2 mutations were found in both tumor cells and non-tumor hematopoietic cells. RHOA encodes a small GTPase that regulates diverse biological processes. We demonstrated that the Gly17Val RHOA mutant did not bind GTP and also inhibited wild-type RHOA function. Our findings suggest that impaired RHOA function in cooperation with preceding loss of TET2 function contributes to AITL-specific pathogenesis.
Assuntos
Proteínas de Ligação a DNA/genética , Linfadenopatia Imunoblástica/genética , Linfoma de Células T Periférico/genética , Proteínas Proto-Oncogênicas/genética , Proteína rhoA de Ligação ao GTP/genética , Animais , Sequência de Bases , Bromodesoxiuridina , DNA (Citosina-5-)-Metiltransferases/genética , DNA Metiltransferase 3A , Dioxigenases , Exoma/genética , Humanos , Isocitrato Desidrogenase/genética , Células Jurkat , Linfoma de Células T Periférico/patologia , Camundongos , Dados de Sequência Molecular , Mutação de Sentido Incorreto/genética , Células NIH 3T3 , Análise de Sequência de DNARESUMO
Bronchiolitis obliterans (BO) is one of the serious, noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early diagnosis of BO is usually difficult because patients are often asymptomatic at an initial stage of the disease and pathologic findings are available mostly at the late stages. Therefore, the diagnosis of the disease is based on the pulmonary function test using the National Institute of Health consensus criteria. Here, we report a case of slowly progressive BO. A biopsy specimen at an early stage demonstrated alveolar destruction with lymphocyte infiltration in bronchial walls and mild narrowing of bronchioles without fibrosis, those were strongly indicative of initial pathologic changes of BO. Definitive BO followed, which was proven by both clinical course and autopsy. While alloreactive lymphocytes associated with chronic graft-versus-host disease are believed to initiate BO, we present a rare case that directly implies such a scenario.